Irene Ghobrial, MD receives SU2C Catalyst grant
PCROWD NEWS


Early treatment may prevent progression to multiple myeloma
Monoclonal gammopathy of unknown significance (MGUS) & importance of regularly monitoring patients
How to use social media in clinical trials - reaching out to patients
Benefits of early therapeutic intervention for high-risk smouldering multiple myeloma patients
How can we improve our understanding of the progression of myeloma?


The genomics behind blood cancers and other blood disorders


Precursor Blood Condition Patient Pays it Forward
How I Treat Smoldering Multiple Myeloma - Irene M. Ghobrial
Treatment is Waiting
Gift funds precursor condition research for blood cancers
Preventing Myeloma Before it Gets Started with Dr. Irene Ghobrial, MD, Dana-Farber Cancer Institute
Irene Ghobrial, MD, explains Dana-Farber's CPOP
Why do Waldenström Macroglobulinemia and Multiple Myeloma change from MGUS to active disease?
Myeloma Crowd: Now Enrolling for PCROWD study: Patients with precursor conditions such as MGUS & Smo


Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes


New Clinic Focuses on Why Some Conditions Become Cancer While Others Don't
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and C